Behzad Aghazadeh insider trades: Scribe Therapeutics (SCTX) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Behzad reports to the SEC
Open-market buys and sales
21 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jul 28, 2026 | SCTX | ↑ Buy | 2,391,238 | $15.16 | $36.3M | Indirect | Jul 28, 2026 (0d) |
| May 1, 2020 | IMMU | ↑ Buy | 1,750,000 | $28.50 | $49.9M | Indirect | May 1, 2020 (0d) |
| Dec 5, 2019 | IMMU | ↑ Buy | 2,000,000 | $17.50 | $35.0M | Indirect | Dec 9, 2019 (4d) |
| Oct 3, 2019 | IMMU | ↑ Buy | 500,000 | $14.10 | $7.0M | Indirect | Oct 4, 2019 (1d) |
| Oct 2, 2019 | IMMU | ↑ Buy | 1,000,000 | $13.23 | $13.2M | Indirect | Oct 4, 2019 (2d) |
| Jul 23, 2019 | MRTX | ↓ Sell | 62,500 | $101.88 | $6.4M | Indirect | Jul 25, 2019 (2d) |
| Jun 28, 2019 | IMMU | ↑ Buy | 600,000 | $13.75 | $8.2M | Indirect | Jun 28, 2019 (0d) |
| Jun 26, 2019 | IMMU | ↑ Buy | 400,000 | $13.25 | $5.3M | Indirect | Jun 28, 2019 (2d) |
| Jun 5, 2019 | IMMU | ↑ Buy | 750,000 | $12.22 | $9.2M | Indirect | Jun 5, 2019 (0d) |
| Jun 3, 2019 | IMMU | ↑ Buy | 785,539 | $12.19 | $9.6M | Indirect | Jun 5, 2019 (2d) |
| May 15, 2019 | IMMU | ↑ Buy | 250,000 | $15.18 | $3.8M | Indirect | May 15, 2019 (0d) |
| May 13, 2019 | IMMU | ↑ Buy | 500,000 | $15.07 | $7.5M | Indirect | May 15, 2019 (2d) |
| Mar 20, 2019 | MRTX | ↓ Sell | 123,781 | $73.31 | $9.1M | Indirect | Mar 20, 2019 (0d) |
| Mar 18, 2019 | MRTX | ↓ Sell | 125,000 | $76.55 | $9.6M | Indirect | Mar 20, 2019 (2d) |
| Feb 20, 2019 | MRTX | ↓ Sell | 686,820 | $73.00 | $50.1M | Indirect | Feb 21, 2019 (1d) |
| Jun 15, 2018 | IMMU | ↑ Buy | 200,000 | $23.39 | $4.7M | Indirect | Jun 19, 2018 (4d) |
| Jun 15, 2018 | IMMU | ↑ Buy | 575,000 | $24.00 | $13.8M | Indirect | Jun 15, 2018 (0d) |
| Jun 11, 2018 | MRTX | ↑ Buy | 400,000 | $38.85 | $15.5M | Indirect | Jun 12, 2018 (1d) |
| Nov 16, 2017 | MRTX | ↑ Buy | 650,000 | $13.00 | $8.4M | Indirect | Nov 16, 2017 (0d) |
| Nov 15, 2017 | IMMU | ↑ Buy | 175,000 | $10.97 | $1.9M | Indirect | Nov 15, 2017 (0d) |
| Nov 14, 2017 | IMMU | ↑ Buy | 1,150,000 | $10.39 | $11.9M | Indirect | Nov 15, 2017 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other SCTX insiders
Open-market trades in the last 12 months
About Behzad Aghazadeh's insider trades
Behzad Aghazadeh is a director at Scribe Therapeutics (SCTX). Since Nov 14, 2017, Behzad has reported 17 open-market purchases worth $241.4M and 4 sales worth $75.1M on SEC Form 4. In the last 12 months: 1 buy ($36.3M).
Their filings also include grants and awards (18 filings), other transactions (6 filings), option exercises (2 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every SCTX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.